Navigation Links
Pharmos Corporation Reports 2011 Fourth Quarter and Full Year Results
Date:2/17/2012

for this trial, costs related to conducting a non-human primate toxicology study and preliminary administrative startup trial costs for the trial that began in the first quarter of 2012. These increases were offset by a reduction of various facility related expenses as the Company continued to reduce overall facility costs.

General and administrative expenses decreased by $181,788 or 15%, from $1,187,335 in 2010 to $1,005,548 in 2011.  The decrease in general and administrative expenses is due to a reduction in every expense category.  Significant reductions occurred in salaries and benefits of $77,000, professional & consulting fees of $55,000 and facility related expenses of $50,000 when comparing 2011 to 2010. The decrease in payroll costs in 2011 reflects lower stock compensation costs and the elimination of an administrative position in 2010. Accounting fees have decreased as there were higher accounting fees related to the filing of a Registration statement on Form S-1 in 2010. Also professional fees have decreased as there were business development fees in 2010 related to a possible reverse merger candidate which eventually was not pursued. The decrease in the facility related expenses were a reduction of various facility related expenses as the Company continued to reduce overall facility costs.

About Pharmos Corporation Pharmos discovers and develops novel therapeutics to treat a range of metabolic and nervous system disorders, including gout, disorders of the brain-gut axis (e.g., Irritable Bowel Syndrome), pain/inflammation, and autoimmune disorders.  The Company's lead products are the two enantiomers of tofisopam. S-tofisopam (levotofisopam) is being investigated for the treatment of gout under a US IND. R-tofisopam (dextofisopam) has been developed through Phase 2b for IBS in the US. There is a large unmet need for new therapeutic alternatives for the treatment of IBS, a chronic and sometimes debilitating condition
'/>"/>

SOURCE Pharmos Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmos Corporation Reports 2011 Second Quarter Results
2. Pharmos Corporation Reports 2010 Third Quarter Results
3. Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
4. Pharmos Corporation Reports 2009 Third Quarter Results
5. Pharmos Issues Business Update on Dextofisopam Trial and Financing
6. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
7. Angeion Corporation to Report First Quarter Fiscal 2012 Financial Results on Tuesday, February 28, 2012
8. Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure
9. Unilife Corporation Announces Financial Results for Fiscal Year 2012 Second Quarter
10. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
11. Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- According to a new market research ... (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air Displacement ... Forecast to 2019", published by MarketsandMarkets, the global Body ... and is estimated to grow to $1,425.7 Million by ... to 2019. Browse 41 market data ...
(Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation (NASDAQ: ... its second quarter 2015 financial results after the market ... conjunction with the release, the Company will host a ... p.m. Eastern Time on Thursday, August 6, ... and other business developments. Interested parties may ...
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle to ... a precautionary measure due to the identification of a ... The risk associated with mistakenly taking ... the increased probability of experiencing Clopidogrel,s side effects which ...
Breaking Medicine Technology:Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... /PRNewswire-Asia/ -- Bristol-Myers Squibb Company (NYSE: ... (NYSE: SCR ), a leading pharmaceutical company ... the strategic partnership formed last year to include a ... agreed to co-develop BMS-795311, Bristol-Myers Squibb,s preclinical small molecule ...
... SAN DIEGO, Dec. 13, 2011  BioMed Realty Trust, Inc. ... has entered into a definitive agreement to acquire Prudential ... Street properties.  BioMed previously acquired a 20% interest in ... venture entered into between BioMed and PREI.  The Rogers ...
Cached Medicine Technology:Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound 2Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound 3Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound 4Biomed Realty Trust to Acquire Remaining 80% Interest in Rogers Street Properties in Cambridge, Massachusetts for $308 Million - Increasing Ownership to 100% 2Biomed Realty Trust to Acquire Remaining 80% Interest in Rogers Street Properties in Cambridge, Massachusetts for $308 Million - Increasing Ownership to 100% 3Biomed Realty Trust to Acquire Remaining 80% Interest in Rogers Street Properties in Cambridge, Massachusetts for $308 Million - Increasing Ownership to 100% 4
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... Have you ever wondered what “Karma” really ... you hear the word “Karma.” , Vedic tradition, which gave birth to Hinduism, is ... one of the central concepts of this tradition. According to the wisdom of this heritage, ...
(Date:8/1/2015)... ... ... Brig and Lita Hart, icons of the network marketing industry and founders of ... the HOPE Movement of EvolvHealth. In what has been a long-term relationship between the ... their missions of purpose together to change the course of the network marketing industry. ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe ... the very first small business donation to kick off the campaign for healing and ... Her legacy includes a complete line of raw, organic hair care products, as well ...
(Date:7/31/2015)... Vegas, NV (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable ... Vegas at the MGM Grand Garden Arena. Fans of every genre of music will ... Friday, September 18th, the first day of the festival, the following artists will perform: ...
(Date:7/31/2015)... ... 31, 2015 , ... Ticket Down is a reliable source for authentic tickets ... Grant Park. The festival will end on Sunday, August 2nd. , ... annual Lollapalooza. This unique and unbelievably popular festival attracts the best in entertainment ...
Breaking Medicine News(10 mins):Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:March4thforWellBeing Foundation Kickoff 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2
... Complimentary Continuing Medical Education Virtual Lecture and Podcast ... Clostridium difficile infection (CDI) is changing ... more severe and complicated disease. Furthermore, the epidemic ... number of states across the United States, and ...
... Corporation (NYSE: CVS ) today announced ... Officer and Chief Administrative Officer, will be making ... Institutional Investors Conference on March 10, 2009. Mr. ... a.m. EDT. (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO )An ...
... Supplement Offers Promising Results for Tired Baby ... Ribose Company(TM)--has announced preliminary findings indicating that ... The results were presented at the Scripps ... and is a patented functional ingredient for ...
... Diabetes patients undergoing team-based care do not save ... than other patients, but they are healthier, according ... a substantial financial burden on patients, payers and ... and administration, Penn State, and lead author of ...
... new article appearing in the March 2009 issue of ... ) may lead to improvements in the efficacy of ... researchers discovered a new role for type I interferon, ... to stimulate an immune response against the bacterium known ...
... It might one day be used as an ingredient in ... Past studies have suggested that caffeine might offer some protection ... "We have found what we believe to be the mechanism ... lead researcher Dr. Paul Nghiem, an associate professor of dermatology ...
Cached Medicine News:Health News:Interview with GI Experts: Discussions in Clostridium difficile 2Health News:CVS Caremark Corporation to Present at the Raymond James Institutional Investors Conference on March 10th 2Health News:Bioenergy Ribose Found to Improve Vitality, Aerobic Fitness and Mental Outlook 2Health News:Bioenergy Ribose Found to Improve Vitality, Aerobic Fitness and Mental Outlook 3Health News:Team-based diabetes care fetches more value for dollar 2Health News:New discovery gives tuberculosis vaccine a shot in the arm 2Health News:Caffeine May Offer Some Skin Cancer Protection 2Health News:Caffeine May Offer Some Skin Cancer Protection 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: